Extended sleeve lobectomy (ESL) is considered a lung-sparing alternative to pneumonectomy (PN) for centrally located non-small cell lung cancer (NSCLC) when standard sleeve lobectomy (SSL) is not feasible. This retrospective study analyzed 94 patients who received neoadjuvant immunochemotherapy followed by either PN, ESL, or SSL.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Cancer
May 1, 2025
The recent CheckMate 816 trial indicated that neoadjuvant chemo-immunotherapy provided limited local control in stage II–III resectable non-small cell lung cancer (NSCLC).
March 18, 2025
This video shows the case of a minimally invasive esophagectomy for stage III gastroesophageal junction adenocarcinoma following permanent dual esophageal stent placement.
March 13, 2025
This study investigates the impact of tumor spread through air spaces (STAS) on surgical outcomes for early-stage non-small cell lung cancer (NSCLC). In a retrospective analysis of 785 patients, 19.2 percent were found to have STAS-positive NSCLC.
February 18, 2025
This video demonstrates the management of a patient at high risk for recurrent laryngeal nerve injury during esophagectomy with preoperative and postoperative true vocal fold injection.
February 6, 2025
This study aimed to explore the impact of socioeconomic disparities on the uptake of neoadjuvant therapy in patients with locally advanced esophageal cancer. Using data from the American National Cancer Database, 19,748 patients were identified with clinical stage II-III esophageal cancer who underwent surgical resection between 2006 and 2020.
Pages
- « first
- ‹ previous
- 1
- 2
- 3
- 4